Patents by Inventor JOHN CHANG-EUN CHA

JOHN CHANG-EUN CHA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FENFLURAMINE FOR TREATMENT OF DEMYELINATING DISEASES AND CONDITIONS
    Publication number: 20230078820
    Abstract: Methods of modifying disease progression of a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are also described herein.
    Type: Application
    Filed: August 25, 2022
    Publication date: March 16, 2023
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: John Chang-Eun CHA, Thaddeus Cromwell REEDER
  • Transgenic mouse expressing human apo(a) and human apo(B-100) with disabled vitamin C gene produces human Lp(a)
    Patent number: 9018437
    Abstract: The invention discloses novel model of transgenic mammal, a method of crossbreeding transgenic mammal and the use of the transgenic mammal for assessing prevention and/or treatment methods for cardiovascular and other diseases related to lipoprotein(a). The transgenic mammal expresses human apolipoprotein (a) (apo(a)) and human apolipoprotein B-100 (apo B-100) genes and produces human lipoprotein (a), apo (a) and apo B-100 and produces no vitamin C. This novel dual transgenic mammal is the ideal model for testing pharmaceutical compounds for efficacy and usefulness in the prevention and/or treatment of human diseases.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: April 28, 2015
    Inventors: Matthias W Rath, Aleksandra Niedzwiecki, John Chang-Eun Cha
  • Transgenic mouse expressing human apo(a) and human apo(B-100) with disabled vitamin C gene produces human Lp(a)
    Publication number: 20150074837
    Abstract: The invention discloses novel model of transgenic mammal, a method of crossbreeding transgenic mammal and the use of the transgenic mammal for assessing prevention and/or treatment methods for cardiovascular and other diseases related to lipoprotein(a). The transgenic mammal expresses human apolipoprotein (a) (apo(a)) and human apolipoprotein B-100 (apo B-100) genes and produces human lipoprotein (a), apo (a) and apo B-100 and produces no vitamin C. This novel dual transgenic mammal is the ideal model for testing pharmaceutical compounds for efficacy and usefulness in the prevention and/or treatment of human diseases.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 12, 2015
    Inventors: MATTHIAS W RATH, Aleksandra Niedzwiecki, JOHN CHANG-EUN CHA
  • TRANSGENIC MOUSE EXPRESSING HUMAN LIPOPROTEIN (A) WITH DISABLED VITAMIN C GENE AND ITS USE AS A DISEASE TREATMENT MODEL
    Publication number: 20150074835
    Abstract: The invention discloses novel model of transgenic mammal, a method of crossbreeding transgenic mammal and the use of the transgenic mammal for assessing prevention and/or treatment methods for cardiovascular and other diseases related to lipoprotein(a). The transgenic mammal expresses human apolipoprotein (a) (apo(a)) and human apolipoprotein B-100 (apo B-100) genes and produces human lipoprotein (a), apo (a) and apo B-100 and produces no vitamin C. This novel dual transgenic mammal is the ideal model for testing pharmaceutical compounds for efficacy and usefulness in the prevention and/or treatment of human diseases.
    Type: Application
    Filed: October 5, 2014
    Publication date: March 12, 2015
    Inventors: MATTHIAS W. RATH, Aleksandra Niedzwiecki, JOHN CHANG-EUN CHA